Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354796 | 0.95 | NCF1 (0.50) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL5943525 | 0.89 | NCF1 (0.55) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL5943486 | 0.89 | NCF1 (0.59) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL15286478 | 0.88 | NCF1 (0.53) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL9850350 | 0.84 | NCF1 (0.57) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL3956730 | 0.83 | TLR8 (0.56) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL4848300 | 0.83 | POLB (0.54) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL1234357 | 0.81 | NCF1 (0.55) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL4848123 | 0.81 | NCF1 (0.50) | NCF1NPC1RAB9AHPGDHSD17B10 | |
| SCHEMBL5943479 | 0.81 | NCF1 (0.59) | NCF1NPC1RAB9AHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247439-A1 | Mchir antagonists | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | disclosed |
| EP-1528924-A1 | MCH1R ANTAGONISTS | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004004726-A1 | MCHIR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1019050-B1 | USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE | NOVO NORDISK AS (DK) | 2002-03-20 | — | — | EP | disclosed |
| US-6159941-A | Use of somatostatin agonists and antagonists for treating diseases related to the eye | NOVO NORDISK A/S (DK) | 2000-12-12 | — | — | US | disclosed |
| US-6127343-A | SELECTIVE, COMPETITIVE SOMATOSTATIN RECEPTOR LIGANDS OF NONPEPTIDE ORIGIN, FOR MEDIATING THE BIOLOGICAL EFFECT OF SOMATOSTATIN AGONISTS OR ANTAGONIST | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| EP-1019050-A1 | USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | disclosed |
| EP-0912551-A1 | SOMATOSTATIN AGONISTS AND ANTAGONISTS | NOVO NORDISK A/S (DK) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998058646-A1 | USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE | NOVO NORDISK A/S (DK) | 1998-12-30 | — | — | WO | disclosed |
| WO-1997043278-A1 | SOMATOSTATIN AGONISTS AND ANTAGONISTS | NOVO NORDISK A/S (DK) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247439-A1 | Mchir antagonists | MCHR1, HCRTR1, MC3R | NCF1 4070/4885NPC1 193/4885RAB9A 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.